Complications in Advanced or Recurrent Gastric Cancer Patients with Peritoneal Metastasis During and After Palliative Systemic Chemotherapy

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2015 Jul 3

PMID 26137263

Citations 13

Authors

Yasuo Hamamoto

Affiliations

Soon will be listed here.

Abstract

Peritoneal metastasis (PM) in gastric cancer (GC) is often the cause of several complications, including ascites and bowel obstruction. The prognosis of patients with extensive PM is poor. There are only limited data available on clinical characteristics regarding the period between the initiation of chemotherapy until the death of the patient. We conducted a retrospective study to determine the frequency of major events during and after palliative chemotherapy in advanced GC patients with PM. The records of patients who received first-line palliative chemotherapy at the Tochigi Cancer Center for locally advanced or metastatic disease were reviewed. The extracted information included treatments received and emerging complications. Overall survival was compared between patients with and those without PM. A total of 97 patients were reviewed and the prevalence of complications with or without concurrent PM were as follows: bowel obstruction: PM, 37% (16/43) and non-PM, 20% (11/54) (P=0.0664); ascites: PM, 49% (21/43) and non-PM, 7% (4/54) (P<0.0001). The clinical characteristics of patients with PM from GC are unique. Therefore, it is crucial to consider PM as a predictive sign and an important factor when making clinical decisions and developing treatment strategies.

Citing Articles

CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer.

Ueda A, Yuki S, Ando T, Hosokawa A, Nakada N, Kito Y Cancers (Basel). 2024; 16(5).

PMID: 38473233 PMC: 10930593. DOI: 10.3390/cancers16050871.

A Nomogram for Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Gastric Cancer.

Ren J, Dai Y, Chao F, Tang D, Gu J, Niu G Clin Med Insights Oncol. 2022; 16:11795549221142095.

PMID: 36532700 PMC: 9751160. DOI: 10.1177/11795549221142095.

Development and validation of an artificial neural network model for non-invasive gastric cancer screening and diagnosis.

Fan Z, Guo Y, Gu X, Huang R, Miao W Sci Rep. 2022; 12(1):21795.

PMID: 36526664 PMC: 9758153. DOI: 10.1038/s41598-022-26477-4.

Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru.

Moya-Salazar J, Caceres E, Blejer J, Gonzalez C, Contreras-Pulache H Ecancermedicalscience. 2021; 15:1289.

PMID: 34824612 PMC: 8580600. DOI: 10.3332/ecancer.2021.1289.

Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.

Ando T, Ueda A, Ogawa K, Motoo I, Kajiura S, Nakajima T In Vivo. 2021; 35(1):475-482.

PMID: 33402499 PMC: 7880732. DOI: 10.21873/invivo.12281.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Matsubara J, Shimada Y, Takashima A, Takahari D, Hirashima Y, Okita N . A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. Jpn J Clin Oncol. 2008; 38(8):540-6. DOI: 10.1093/jjco/hyn062. View

Vanhoefer U, Rougier P, Wilke H, Ducreux M, Lacave A, Van Cutsem E . Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the.... J Clin Oncol. 2000; 18(14):2648-57. DOI: 10.1200/JCO.2000.18.14.2648. View

Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H . Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2002; 21(1):54-9. DOI: 10.1200/JCO.2003.04.130. View

Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H . Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011; 14(1):72-80. PMC: 3056989. DOI: 10.1007/s10120-011-0009-5. View

Kim J, Ryoo B, Park Y, Kim B, Kim T, Im Y . Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2007; 61(2):301-7. DOI: 10.1007/s00280-007-0476-x. View

Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C . Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008; 19(8):1450-1457. DOI: 10.1093/annonc/mdn166. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Lee S, Lee J, Ryu M, Chang H, Kim T, Kang H . Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol. 2007; 37(1):30-7. DOI: 10.1093/jjco/hyl134. View

10.

Lee J, Lim T, Uhm J, Park K, Park S, Lee S . Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007; 18(5):886-91. DOI: 10.1093/annonc/mdl501. View

11.

Webb A, Cunningham D, Scarffe J, Harper P, Norman A, Joffe J . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15(1):261-7. DOI: 10.1200/JCO.1997.15.1.261. View

12.

Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K . Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2009; 21(1):67-70. DOI: 10.1093/annonc/mdp260. View

13.

Ajani J, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V . Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010; 28(9):1547-53. DOI: 10.1200/JCO.2009.25.4706. View

14.

Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M . Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013; 43(10):972-80. DOI: 10.1093/jjco/hyt114. View

15.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

16.

Chau I, Norman A, Cunningham D, Waters J, Oates J, Ross P . Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004; 22(12):2395-403. DOI: 10.1200/JCO.2004.08.154. View

17.

Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A . Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009; 10(11):1063-9. DOI: 10.1016/S1470-2045(09)70259-1. View

18.

Kang Y, Kang W, Shin D, Chen J, Xiong J, Wang J . Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009; 20(4):666-73. DOI: 10.1093/annonc/mdn717. View

19.

Wils J, Klein H, Wagener D, Bleiberg H, Reis H, Korsten F . Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991; 9(5):827-31. DOI: 10.1200/JCO.1991.9.5.827. View

20.

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M . S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9(3):215-21. DOI: 10.1016/S1470-2045(08)70035-4. View